Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Abdera Therapeutics Expands Management Team and Board of Directors
MENLO PARK, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced it has raised $142 million in combined Series A and B financing. Versant Ventures and Amplitude Ventures led the Series A round, with participation from Northview Ventures as well as founding partners of Abdera, adMare BioInnovations and AbCellera. The Series B round was led by venBio Partners with participation from existing investors as well as new investors including Viking Global Investors, Qiming Venture Partners USA and RTW Investments.
Lori Lyons-Williams has always been drawn to working in oncology. For the former Allergan leader and Neumora president, there are few opportunities more impactful than treating cancer—and tough-to-target solid tumors at that.